In this episode of Looking Ahead with Blair Jones, Managing Director at Semler Brossy Consulting Group LLC, and Judy Zagorski, EVP of Global Human Resources at Church & Dwight Co., Inc, we focus on key issues specific to succession planning, its intersection with compensation, who should be involved in the process, and more.
Many retailers faced major issues prior to the crisis, which has led to threats on their future with sales plummeting due to shelter-in-place orders. Now, as states reopen, how retailers respond could determine their survival.
Boards must prepare for when things begin returning to normal again. How a company bounces back from this devastation could determine its survival.
The healthcare industry has been a fountain of dealmaking lately. Companies wanting to make acquisitions or sell businesses this year should learn from the experts.
Investors are asking more about a company’s workforce, and companies may be forced to tell them. Last fall, the U.S. Securities and Exchange Commission proposed several changes to disclosure requirements for public companies, among them a provision to enhance disclosure about “human capital.” The rule has not been finalized.
A new disclosure requirement that’s described as the most significant change to the auditor’s report in 70 years is making a difference in the internal controls at large companies, although those looking for scandal so far have been disappointed.
If history is any guide, new audit and accounting requirements such as critical audit matters (CAMs), which went into effect last year, could translate to an increase in fees.
Accounting missteps can reverberate throughout an organization. Mike Shmerling, chairman of Clearbrook Holdings, and Tony Klaich, Managing Partner at Crowe, discuss ways senior leadership can prevent mayhem.
Is the United States ready for “private techquity”? That’s the name a consulting company gave to the adoption of technology in private equity, including machine learning and data-heavy databases.
December 17, 2019 Cyber
Artificial intelligence and big data offer some of the most exciting prospects for medicine. But making good use of the data is another story.